Stephanie Kao is a Chicago, Illinois based female rheumatologist who is specialized in Rheumatology. Active license number of Stephanie Kao for Rheumatology is 036.165579 in Illinois. Stephanie Kao treat joint disease similar to orthopedists but do not perform surgeries. She diagnose and treat diseases of joints, muscle, bones and tendons which includes arthritis, back pain, muscle strains, common athletic injuries and 'collagen' diseases.
Complete Profile:
Stephanie Kao speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Rheumatology
Credentials:
MD
Gender:
Female
Practice Address:
676 N Saint Clair St Ste 2330, Chicago, Illinois, 60611-2915
Phone:
312-926-6895
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1861011710
NPI Enumeration Date:
10 Apr, 2020
NPI Last Update On:
25 Jul, 2023
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Stephanie Kao are as mentioned below.
License Number
Specialization
State
Status
036.165579
Rheumatologist
Illinois
Primary
Student in an Organized Health Care Education/Training Program
Secondary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
676 N Saint Clair St Ste 2330, Chicago, Illinois
Zip:
60611-2915
Phone Number:
--
Fax Number:
--
Patients can reach Stephanie Kao at 676 N Saint Clair St Ste 2330, Chicago, Illinois or can call to book an appointment on 312-926-6895. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.